Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo G Carrera

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Archives of Dermatological Research|August 8, 2012
Not simply a matter of psoriatic arthritis: epidemiology of rheumatic diseases in psoriatic patientsGabriele De Marco, Angelo Cattaneo, Norma Battafarano, et al.
Drug Development Research|November 11, 2014
The EPIPSOFIRE project: a preliminary reportGabriele De Marco, Angelo Cattaneo, Carlo G Carrera, et al.
Journal of Drugs in Dermatology : JDD|December 21, 2020
Predicting Secukinumab Fast-Responder Profile in Psoriatic Patients: Advanced Application of Artificial-Neural-Networks (ANNs)Giovanni Damiani, Rosalynn R Z Conic, Paolo D M Pigatto, et al.
Dermatology and Therapy|October 13, 2024
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Dermatologic Therapy|May 31, 2022
Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis)Piergiorgio Malagoli, Paolo Dapavo, Giulia Pavia, et al.
The Journal of Dermatological Treatment|January 27, 2025
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study - IL PSO (Italian landscape psoriasis)Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
Dermatology and Therapy|May 21, 2023
Real-World Experience of Methotrexate in the Treatment of Skin Diseases: an Italian Delphi ConsensusGiovanni Damiani, Paolo Amerio, Federico Bardazzi, et al.
Frontiers in Immunology|January 26, 2024
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy|May 15, 2024
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2023
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Archives of Dermatological Research|August 8, 2012
Not simply a matter of psoriatic arthritis: epidemiology of rheumatic diseases in psoriatic patientsGabriele De Marco, Angelo Cattaneo, Norma Battafarano, et al.
Drug Development Research|November 11, 2014
The EPIPSOFIRE project: a preliminary reportGabriele De Marco, Angelo Cattaneo, Carlo G Carrera, et al.
Journal of Drugs in Dermatology : JDD|December 21, 2020
Predicting Secukinumab Fast-Responder Profile in Psoriatic Patients: Advanced Application of Artificial-Neural-Networks (ANNs)Giovanni Damiani, Rosalynn R Z Conic, Paolo D M Pigatto, et al.
Dermatology and Therapy|October 13, 2024
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Dermatologic Therapy|May 31, 2022
Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis)Piergiorgio Malagoli, Paolo Dapavo, Giulia Pavia, et al.
The Journal of Dermatological Treatment|January 27, 2025
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study - IL PSO (Italian landscape psoriasis)Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
Dermatology and Therapy|May 21, 2023
Real-World Experience of Methotrexate in the Treatment of Skin Diseases: an Italian Delphi ConsensusGiovanni Damiani, Paolo Amerio, Federico Bardazzi, et al.
Frontiers in Immunology|January 26, 2024
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy|May 15, 2024
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2023
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Pageof 2